J&J Insiders Exercise $15.9M in Stock Options Amid Compensation Season

Five Johnson & Johnson (NYSE: JNJ) executives exercised stock options and received awards totaling $15.9 million between February 13-17, 2026, according to SEC filings, marking a concentrated period of insider activity typical of annual compensation cycles.

The Trades

The cluster involved 21 transactions across five senior executives, dominated by option exercises and tax-related share payments. EVP and Chief Information Officer James D. Swanson led the group with the largest single transaction — exercising 20,521 shares at $164.62 per share for a total value of $3.4 million on February 17.

The timing appears coordinated with Johnson & Johnson's annual equity compensation schedule, as all five executives received restricted stock awards on February 15, ranging from 16,945 to 20,322 shares granted at no cost. These awards typically vest over multiple years and represent long-term incentive compensation.

Notably, the executives paid taxes on their option exercises through share withholding at prices between $243.45 and $244.55 per share, indicating the stock's trading range during the period. This tax payment method, where shares are automatically withheld to cover tax obligations, is standard practice for executive compensation and reduces the net shares received.

Who's Trading

The insider group represents J&J's senior leadership across critical business functions:

James D. Swanson, Executive Vice President and Chief Information Officer, conducted the most activity with eight separate transactions. His February 17 exercise of 20,521 shares at $164.62 represented options likely granted years earlier when J&J's stock traded significantly lower, resulting in substantial paper gains.

Joseph J. Wolk, Executive Vice President and Chief Financial Officer, exercised 37,463 shares on February 13, though the exercise price was not disclosed in the filing. As CFO, Wolk's participation in this compensation event alongside other executives suggests routine annual activity rather than trading on specific company developments.

Kathryn E. Wengel, EVP and Chief Technology and Risk Officer, executed five transactions including exercises on February 13 and 15, plus a 16,945-share award. The dual role overseeing both technology and risk makes her position particularly strategic as J&J navigates digital transformation.

Kristen Mulholland, EVP and Chief Human Resources Officer, completed five transactions following the same pattern as other executives — exercises, tax payments, and a 20,322-share award on February 15.

The synchronous nature of these transactions, particularly the February 15 equity awards and the February 13 and 15 exercise dates, points to predetermined trading windows established by J&J's insider trading policy. Companies typically designate specific periods when executives can exercise options and trade shares to avoid any appearance of trading on material non-public information.

What to Watch

This insider cluster reflects standard compensation practices rather than discretionary trading decisions. The absence of open-market purchases or sales — transactions where insiders use their own capital to buy shares or sell existing holdings — suggests these moves are administrative rather than signals about J&J's prospects.

The $164.62 exercise price on Swanson's February 17 transaction provides insight into J&J's historical stock performance. With shares trading around $244 during the tax withholding transactions, these options delivered approximately 48% gains from their grant price, indicating they were likely issued several years ago during a period of lower valuations.

For context, insider option exercises often cluster around specific dates due to vesting schedules, expiration deadlines, or tax planning considerations. The February timing aligns with many companies' annual compensation cycles, when new equity awards are granted and previous awards vest.

Investors should note that while this $15.9 million in total transaction value appears substantial, it represents routine compensation activity for a company of J&J's size, with a market capitalization exceeding $400 billion. The simultaneous awards granted to all executives on February 15 signal the company's ongoing use of equity compensation to align executive interests with shareholders.

The lack of any outright sales at market prices — where executives sell shares for cash rather than just covering tax obligations — suggests these insiders remain invested in J&J's future. The restricted stock awards will likely vest over the coming years, maintaining these executives' substantial equity stakes in the pharmaceutical giant.

*Source: SEC Form 4 filings, February 13-23, 2026*

*StockCliff Research*